RTP Mobile Logo
Select Publications

Albain KS et al. Race, ethnicity, and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. J NatlCancer Inst 2021;113(4):390-9. Abstract

Bardia A et al. Phase I study of elacestrant (RAD1901), a novel selective estrogen receptor degrader, in ER-positive, HER2-negative advanced breast cancer. J Clin Oncol2021;39(12):1360-70. Abstract

Campone M et al. AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) PIK3CA-mutated advanced breast cancer. ESMO 2021;Abstract 333TiP.

Chandarlapaty S et al. AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor 2-negative (HER2–) advanced breast cancer (aBC). ESMO 2021;Abstract 264P.

Hortobagyi GN et al. Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB). ESMO 2021;Abstract LBA17_PR.

Hurvitz SA et al. Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study. ESMO 2021;Abstract LBA14.

Johnston SRD et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 2020;38(34):3987-98. Abstract

Jones RH et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): A multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2020;21(3):345-57. Abstract

Kalinsky K et al. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder). SABCS 2020;Abstract GS3-00.

Koca E et al. ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat 2021;188(2):433-9. Abstract

Paluch-Shimon S et al. Adjuvant endocrine therapy combined with abemaciclib in monarchE patients with high-risk early breast cancer: Disease characteristics and endocrine therapy choice by menopausal status. ESMO 2021;Abstract 153P.

Sparano JA et al. Clinical outcomes in early breast cancer with a high 21-gene Recurrence Score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: A secondary analysis of the TAILORx randomized clinical trial. JAMA Oncol 2020;6(3):367-74. Abstract

Tutt ANJ et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 2021;384(25):2394-405. Abstract

Weiss MC et al. A survey of breast cancer patients’ use of cannabis before, during, and after treatment. ASCO 2020;Abstract e19210.

Wu S et al. Subtype-guided 18F-FDG PET/CT in tailoring axillary surgery among patients with node-positive breast cancer treated with neoadjuvant chemotherapy: A feasibility study. Oncologist 2020;25(4):e626-33. Abstract

Yap YS et al. Longitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) + endocrine therapy (ET) in Asian patients (pts) with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC). ESMO 2021;Abstract 232P.